Zobrazeno 1 - 10
of 630
pro vyhledávání: '"Michel, Ducreux"'
Autor:
Vladimir Lazar, Eric Raymond, Shai Magidi, Catherine Bresson, Fanny Wunder, Ioana Berindan-Neagoe, Annemilaï Tijeras-Rabaland, Jacques Raynaud, Amir Onn, Michel Ducreux, Gerald Batist, Ulrik Lassen, Fin Cilius Nielsen, Richard L. Schilsky, Eitan Rubin, Razelle Kurzrock
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options. Objective: Considering the hypothesis that central hubs are associated with increased leth
Externí odkaz:
https://doaj.org/article/da12cb09d31d4454bd2113b0c027167a
Autor:
Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Publikováno v:
Liver Cancer (2024)
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpo
Externí odkaz:
https://doaj.org/article/d51ee563349d44e9ad5aa1c2a8eccf42
Autor:
René Adam, David Badrudin, Laurence Chiche, Petru Bucur, Olivier Scatton, Victoire Granger, Michel Ducreux, Umberto Cillo, François Cauchy, Mickael Lesurtel, Jean-Yves Mabrut, Chris Verslype, Laurent Coubeau, Jean Hardwigsen, Emmanuel Boleslawski, Fabrice Muscari, Heithem Jeddou, Denis Pezet, Bruno Heyd, Valerio Lucidi, Karen Geboes, Jan Lerut, Pietro Majno, Lamiae Grimaldi, Nadjia Boukhedouni, Céline Piedvache, Maximiliano Gelli, Francis Levi, Maïté Lewin
Publikováno v:
EClinicalMedicine, Vol 72, Iss , Pp 102608- (2024)
Summary: Background: Despite the increasing efficacy of chemotherapy (C), the 5-year survival rate for patients with unresectable colorectal liver metastases (CLM) remains around 10%. Liver transplantation (LT) might offer a curative approach for pat
Externí odkaz:
https://doaj.org/article/c657bd04bfd043768772e28d4a626146
Autor:
Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque, Sophie Postel-Vinay
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Biliary tract cancers (BTCs) are heterogeneous malignancies with dismal prognosis due to tumor aggressiveness and poor response to limited current therapeutic options. Tumor exome profiling has allowed to successfully establish targeted ther
Externí odkaz:
https://doaj.org/article/0e99e403d1d04ae1bc389c998b7b3798
Autor:
Jérôme Cartry, Sabrina Bedja, Alice Boilève, Jacques R. R. Mathieu, Emilie Gontran, Maxime Annereau, Bastien Job, Ali Mouawia, Pierre Mathias, Thierry De Baère, Antoine Italiano, Benjamin Besse, Isabelle Sourrouille, Maximiliano Gelli, Mohamed-Amine Bani, Peggy Dartigues, Antoine Hollebecque, Cristina Smolenschi, Michel Ducreux, David Malka, Fanny Jaulin
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background Patient Derived Organoids (PDOs) emerged as the best technology to develop ex vivo tumor avatars. Whether drug testing on PDOs to identify efficient therapies will bring clinical utility by improving patient survival remains uncle
Externí odkaz:
https://doaj.org/article/0d8a07fdb2e64fafb7f7082f91aca715
Autor:
Paul Matte, Michel Ducreux
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 474-477 (2023)
Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low
Externí odkaz:
https://doaj.org/article/8e642e83f25346ae9d1d491cf09ba498
Autor:
Vladimir Lazar, Baolin Zhang, Shai Magidi, Christophe Le Tourneau, Eric Raymond, Michel Ducreux, Catherine Bresson, Jacques Raynaud, Fanny Wunder, Amir Onn, Enriqueta Felip, Josep Tabernero, Gerald Batist, Razelle Kurzrock, Eitan Rubin, Richard L. Schilsky
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate in patient enrollment in early phase trials and a high failure rate of drugs in phase III studies. Objective: Integrating t
Externí odkaz:
https://doaj.org/article/59159a57b2d143e3be0bcdbaf9afc021
Autor:
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption
Externí odkaz:
https://doaj.org/article/6af5eea42a484415bfabf884579086db
Autor:
Anthony Tarabay, Alice Boileve, Cristina Smolenschi, Leony Antoun, Marine Valery, Alina Fuerea, Audrey Perret, Pascal Burtin, Simona Cosconea, Hichem Belkhodja, David Malka, Valérie Boige, Antoine Hollebecque, Michel Ducreux
Publikováno v:
Biomedicines, Vol 11, Iss 9, p 2569 (2023)
Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of death by cancer worldwide. Mostly diagnosed with locally advanced or metastatic disease, patients lack treatment options. Gene alterations (GAs) are frequently observed
Externí odkaz:
https://doaj.org/article/26a3fb018c8542f2bb1c09dce554c516
Autor:
Eugénie Rigault, Benjamin Lacas, Olivier Glehen, Denis Smith, Eric Dupont-Bierre, Rosine Guimbaud, David Malka, Valérie Boige, Alina Fuerea, Jean-Pierre Pignon, Michel Ducreux
Publikováno v:
Cancer Treatment and Research Communications, Vol 34, Iss , Pp 100674- (2023)
Introduction: Intra-arterial hepatic (IAH) treatment has shown promising results in the management of patients with unresectable colorectal liver metastases (CRLM) the prognosis of which is poor. Bevacizumab adjunction to standard chemotherapy has be
Externí odkaz:
https://doaj.org/article/c22bcb3444d34782a25dee5d64cfa6c8